Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466162 | 0.90 | MET (0.60) | METUSP2PKMALOX15ATM | |
| SCHEMBL3117528 | 0.90 | MET (0.59) | METUSP2PKMALOX15ATM | |
| SCHEMBL13249462 | 0.88 | MET (0.76) | METUSP2PKMALOX15ATM | |
| Hydrochloric Acid SCHEMBL2673060 | 0.87 | HDAC1 (0.58) | METMEN1KMT2ATP53MAPT | |
| SCHEMBL2466985 | 0.87 | MET (0.56) | METMEN1KMT2A | |
| SCHEMBL2467254 | 0.87 | MET (0.56) | METUSP2PKMALOX15ATM | |
| SCHEMBL2468839 | 0.86 | MET (0.60) | MET | |
| SCHEMBL2466186 | 0.85 | MET (0.60) | MET | |
| SCHEMBL2470219 | 0.85 | MET (0.62) | METMEN1KMT2AMAPT | |
| SCHEMBL2468273 | 0.85 | MET (0.61) | METMEN1KMT2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885USP2 3593/4885PKM 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.